Madam, Sir, Dear shareholder,

​

Welcome to our Investor Relations page, and thank you for your continued interest in our Company.

​

IMPLANET achieved significant progress in 2025, with revenue reaching €12.5 million, representing a +33% increase compared to the same period last year. This performance confirms the relevance of the development model deployed over the past two years. With six consecutive quarters of sustained growth, we remain firmly optimistic about the business outlook for the coming quarters.

The sales momentum for our implants, up +36% in the last quarter, is supported by continued account openings in the French market, new international market entries, and the first JAZZ® surgeries performed in China.
The distribution of medical equipment, which has grown strongly, is proving to be a valuable diversification and now represents 31% of our total revenue.
 

The integration of robotics into our commercial offering — without requiring additional R&D investment — will quickly position us as a global player.

 

Building on these achievements, we look to the future with confidence, guided by several strategic priorities:

​

• Finalize the registration of our existing products under the European Medical Device Regulation (MDR) and the FDA 510(k) processes;

​​

• Strengthen our presence in the United States by expanding our commercial resources and broadening our scientific team of key opinion leaders;

​​

• Further deploy our commercial and technological partnership with Sanyou Medical;

​​

• Continue developing the distribution of advanced medical equipment in Europe, such as the ultrasonic scalpel from SMTP Technology Co.;

​​

• Position IMPLANET as a trusted partner for surgeons and healthcare institutions in the fields of Artificial Intelligence and robotics adapted to our implant solutions.

​​

On behalf of the entire IMPLANET team, I would like to thank you for your continued trust and support.

Ludovic Lastennet
General manager